{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:37:41Z","timestamp":1786747061010,"version":"build-2736575974"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In late 2025, the US Food and Drug Administration (FDA) made an unprecedented announcement about approving leucovorin for autism symptoms. But the data for its use in autism is flawed. It has only been shown to be safe and effective in a rare genetic syndrome caused by a mutation in the folate receptor alpha gene (FOLR1-CFTD), for which FDA approval was granted in March 2026. Yet patients with autism are already seeking leucovorin. Why is this important in oncology? This approval could impact patients with cancer, where leucovorin is regularly used to mitigate high-dose methotrexate toxicity and enhance fluorouracil efficacy. Leucovorin shortages have been common since 2008. An increased demand for leucovorin for autistic symptoms could limit the available supply for patients with life-threatening cancers. Previous leucovorin drug shortages have led to poorer outcomes by use of less effective regimens, increased real and near-miss errors, decreased clinical trial enrollment, and increased costs. The oncology healthcare team can play a crucial role in minimizing the impact of the off-label use of leucovorin on the care of patients with cancer. As healthcare providers, we need to ensure that access to medications is available only for indications that are based on sound science and peer-reviewed research or are available within a clinical trial.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag304","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:51:24Z","timestamp":1785498684000},"source":"Crossref","is-referenced-by-count":0,"title":["HopeFOL, or FOL of problems? Leucovorin for autistic symptoms"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-0224","authenticated-orcid":false,"given":"Lisa M","family":"Holle","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Pharmacy, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Kratz","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, William S. Middleton Memorial Veterans Hospital , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N","family":"Dow-Hillgartner","sequence":"additional","affiliation":[{"name":"UW Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53792,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Deming","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Uboha","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Lubner","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle K","family":"LoConte","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center , Madison, WI 53705,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026081418170641400_oyag304-B1","author":"US Food and Drug Administration"},{"key":"2026081418170641400_oyag304-B2","author":"US Food and Drug Administration"},{"key":"2026081418170641400_oyag304-B3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJMp2516268","article-title":"Cerebral folate deficiency, autism, and the role of leucovorin","volume":"394","author":"Goldman","year":"2026","journal-title":"N Engl J Med"},{"key":"2026081418170641400_oyag304-B4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(26)00243-6","article-title":"Changes in paracetamol and leucovorin use after a white house briefing","volume":"407","author":"Faust","year":"2026","journal-title":"Lancet"},{"key":"2026081418170641400_oyag304-B5","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1021\/ja01133a015","article-title":"Chemistry of leucovorin","volume":"74","author":"Cosulich","year":"1952","journal-title":"J Am Chem Soc"},{"key":"2026081418170641400_oyag304-B6","author":"Leucovorin Calcium","year":"2026"},{"key":"2026081418170641400_oyag304-B7","first-page":"624","volume-title":"Cancer Chemotherapy Handbook","author":"Leucovorin Calcium","year":"1994","edition":"2nd ed"},{"key":"2026081418170641400_oyag304-B8","doi-asserted-by":"publisher","first-page":"1450418","DOI":"10.3389\/fphar.2024.1050418","article-title":"The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity","volume":"15","author":"Peters","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026081418170641400_oyag304-B9","doi-asserted-by":"publisher","first-page":"e0163961","DOI":"10.1371\/journal.pone.0163961","article-title":"Folic acid-metabolizing enzymes regulator the antitumor effect of 5-fluoro-2\u2032-deoxyuridine in colorectal cancer cell lines","volume":"11","author":"Tsukihara","year":"2016","journal-title":"PLoS One"},{"key":"2026081418170641400_oyag304-B10","doi-asserted-by":"publisher","first-page":"1003812","DOI":"10.3389\/fphar.2022.1003812","article-title":"Association between high-dose methotrexate-induced toxicity and polymorphisms within the methotrexate pathway genes in acute lymphoblastic leukemia","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026081418170641400_oyag304-B11","author":"Leucovorin Calcium Injection","year":"2022"},{"key":"2026081418170641400_oyag304-B12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/2121548a0","article-title":"Eradication of leukaemic cells (L 1210) by methotrexate and methotrexate plus citrovorum factor","volume":"212","author":"Goldin","year":"1966","journal-title":"Nature"},{"key":"2026081418170641400_oyag304-B13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1021\/bi00700a012","article-title":"Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate","volume":"13","author":"Santi","year":"1974","journal-title":"Biochem (Basel)"},{"key":"2026081418170641400_oyag304-B14","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1021\/bi00612a022","article-title":"Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2\u2032-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism","volume":"17","author":"Danenberg","year":"1978","journal-title":"Biochem (Basel)"},{"key":"2026081418170641400_oyag304-B15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/1097-0142(19890315)63:6+<1008::AID-CNCR2820631303>3.0.CO;2-Z","article-title":"Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase","volume":"53","author":"Moran","year":"1989","journal-title":"Cancer"},{"key":"2026081418170641400_oyag304-B16","first-page":"45944","volume":"90","author":"Approval of previously withdrawn new drug application for WELLCOVORIN (leucovorin calcium) tablets","year":"2025","journal-title":"Fed Reg"},{"key":"2026081418170641400_oyag304-B17","author":"US Food and Drug Administration","year":"2025"},{"key":"2026081418170641400_oyag304-B18","author":"U.S. Food and Drug Administration"},{"key":"2026081418170641400_oyag304-B19","first-page":"49780","article-title":"Injection, 175 milligrams\/17.5 milliliters and 250 milligrams\/25 milliliters, were not withdrawn from sale for reasons of safety or effectiveness","volume":"79","author":"Determination That FUSILEV (Levoleucovorin Calcium)","year":"2014","journal-title":"Fed Reg"},{"key":"2026081418170641400_oyag304-B20","author":"American Society of Health-System Pharmacists (ASHP)","year":"2024"},{"key":"2026081418170641400_oyag304-B21","author":"American Society of Health-System Pharmacists (ASHP","year":"2024"},{"key":"2026081418170641400_oyag304-B22","first-page":"1","article-title":"Impact of drug shortages on cancer care delivery within national cancer institute community oncology research program","volume":"22","author":"Ghazal","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026081418170641400_oyag304-B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/OP.23.00545","article-title":"Drug shortages in oncology: ASCO clinical guidance for alternative treatments","volume":"20","author":"Santos","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026081418170641400_oyag304-B24","author":"U.S. Food and Drug Administration (FDA)","year":"2019"},{"key":"2026081418170641400_oyag304-B25","doi-asserted-by":"publisher","first-page":"693426","DOI":"10.3389\/fphar.2021.693426","article-title":"Drug shortage: causes, impact, and mitigation strategies","volume":"12","author":"Shukar","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026081418170641400_oyag304-B26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JOP.2014.00151","article-title":"Chemotherapy drug shortages in the United States revisited","volume":"10","author":"Kantarjian","year":"2014","journal-title":"J Oncol Pract"},{"key":"2026081418170641400_oyag304-B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PPO.0000000000000784","article-title":"Oncology drug shortages: impacts, policy reforms, and advocacy imperatives","volume":"31","author":"Malta","year":"2025","journal-title":"Cancer J"},{"key":"2026081418170641400_oyag304-B28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2146\/ajhp130569","article-title":"Impact of shortages of injectable oncology drugs on patient care","volume":"71","author":"Goldsack","year":"2014","journal-title":"Am J Health Syst Pharm."},{"key":"2026081418170641400_oyag304-B29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2146\/ajhp120563","article-title":"National survey on the effect of oncology drug shortages on cancer care","volume":"70","author":"McBride","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"2026081418170641400_oyag304-B30","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1200\/OP.21.00883","article-title":"National survey on the effect of oncology drug shortages in clinical practice: a hematology oncology pharmacy association survey","volume":"18","author":"McBride","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026081418170641400_oyag304-B31","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"2026081418170641400_oyag304-B32","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMp1212468","article-title":"The impact of drug shortages on children with cancer\u2013the example of mechlorethamine","volume":"367","author":"Metzger","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081418170641400_oyag304-B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/OP.24.00394","article-title":"Impact of an etoposide chemotherapy shortage on patients with extensive-stage small-cell lung cancer: results of a natural experiment","volume":"21","author":"Browne","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"2026081418170641400_oyag304-B34","first-page":"264","article-title":"Lessons from the leucovorin shortages between 2009 and 2012 in a Medicare advantage population: where do we go from here?","volume":"7","author":"Hayes","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"2026081418170641400_oyag304-B35","author":"Pfizer"},{"key":"2026081418170641400_oyag304-B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/codi.14746","article-title":"Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis","volume":"22","author":"Hsu","year":"2020","journal-title":"Colorectal Dis"},{"key":"2026081418170641400_oyag304-B37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R","article-title":"A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo clinic\/North Central cancer treatment group study","volume":"63","author":"O\u2019Connell","year":"1989","journal-title":"Cancer"},{"key":"2026081418170641400_oyag304-B38","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.1989.7.10.1419","article-title":"The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial","volume":"7","author":"Petrelli","year":"1989","journal-title":"J Clin Oncol"},{"key":"2026081418170641400_oyag304-B39","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1200\/JCO.1991.9.11.1967","article-title":"Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer","volume":"9","author":"Poon","year":"1991","journal-title":"J Clin Oncol"},{"key":"2026081418170641400_oyag304-B40","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1200\/JCO.1995.13.6.1303","article-title":"Phase II study of fluorouracil and its modulation in advanced colorectal cancer. A southwest oncology group study","volume":"13","author":"Leichman","year":"1995","journal-title":"J Clin Oncol."},{"key":"2026081418170641400_oyag304-B41","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1200\/JCO.1996.14.8.2274","article-title":"Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multi-center trial","volume":"14","author":"Jager","year":"1996","journal-title":"J Clin Oncol"},{"key":"2026081418170641400_oyag304-B42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00000421-199806000-00004","article-title":"A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer","volume":"21","author":"Ychou","year":"1998","journal-title":"Am J Clin Oncol."},{"key":"2026081418170641400_oyag304-B43","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(00)02214-5","article-title":"Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomized trial","volume":"355","author":"Group","year":"2000","journal-title":"Lancet"},{"key":"2026081418170641400_oyag304-B44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1078155215623085","article-title":"High-versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer","volume":"23","author":"Reynolds","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2026081418170641400_oyag304-B45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1078155215624262","article-title":"Effects of the leucovorin shortage: pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable or metastatic colorectal cancer","volume":"23","author":"Shank","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2026081418170641400_oyag304-B46","doi-asserted-by":"publisher","first-page":"100835","DOI":"10.1016\/j.spen.2020.100835","article-title":"Treatment of folate metabolism abnormalities in autism spectrum disorder","volume":"35","author":"Frye","year":"2020","journal-title":"Semin Pediatr Neurol"},{"key":"2026081418170641400_oyag304-B47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/jimd.12092","article-title":"Cerebral folate deficiency: analytical tests and differential diagnosis","volume":"42","author":"Pope","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2026081418170641400_oyag304-B48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/mp.2016.168","article-title":"Folinic acid improves verbal communication in children with autism and language impairment: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Frye","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2026081418170641400_oyag304-B49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biochi.2020.04.019","article-title":"Folinic acid improves the score of autism in the EFFET placebo-controlled randomized trial","volume":"173","author":"Renard","year":"2020","journal-title":"Biochimie"},{"key":"2026081418170641400_oyag304-B50","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1007\/s00431-024-05762-6","article-title":"Efficacy of oral folinic acid supplementation in children with autism spectrum disorder: a randomized, placebo-controlled trial","volume":"183","author":"Panda","year":"2024","journal-title":"Eur J Pediatr"},{"key":"2026081418170641400_oyag304-B51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00431-026-06769-x","article-title":"Retraction note: efficacy of oral folinic acid supplementation in children with autism spectrum disorder: a randomized double-blind, placebo-controlled trial","volume":"185","author":"Panda","year":"2026","journal-title":"Eur J Pediatr"},{"key":"2026081418170641400_oyag304-B52","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2025.19739","article-title":"Leucovorin not recommended for autism","volume":"334","author":"AAP","year":"2025","journal-title":"JAMA"},{"key":"2026081418170641400_oyag304-B53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/wvn.12621","article-title":"Evidence-based practice improves patient outcomes and healthcare system return on investment: findings from a scoping review","volume":"20","author":"Connor","year":"2023","journal-title":"Worldviews Evid Based Nurs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag304\/70413014\/oyag304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag304\/70413014\/oyag304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag304\/70413014\/oyag304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:17:13Z","timestamp":1786745833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag304\/8748505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag304","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,31]]},"article-number":"oyag304"}}